



Memo

CEC TRIM Ref: D14/12399-12

TO: Chief Executives, Local Health Districts/ Specialty Health Networks

CC: Directors of Clinical Governance, Local Health Districts/ Specialty Health Networks

FROM: Professor Cliff Hughes, Chief Executive Officer

TEL: 02 9269-5585

DATE:

1 October 2014

SUBJECT: Safety Notice SN003/14 – Potassium Chloride BP 10mmol/10mL ampoules disruption to supply

The attached Safety Notice SN003/14 – “Potassium Chloride BP 10mmol/10mL ampoules disruption to supply” released on 4 August 2014 indicated disruption to supply was likely to continue until early to mid-September.

We have been recently advised that the unavailability of potassium chloride BP 10mmol/10mL ampoules AUST R 10793 (Pfizer Australia Pty Ltd) is now likely to continue until early November, subject to the manufacturer being able to renew supplies at this time. Emergency supply arrangements have been put in place by AstraZeneca for the alternative supply of potassium chloride in a 10mmol/10mL ampoule during this period. Updates on stock availability and supply options can be obtained by emailing contract902@hss.health.nsw.gov.au.

We request that in the interim LHDs/Networks continue to follow the measures outlined in the Safety Notice SN003/14 until supply is reinstated.

Should you require any further information please contact Ms Nina Muscillo on 02 9269 5585.

Yours sincerely

Clifford F Hughes AO
CLINICAL PROFESSOR
CHIEF EXECUTIVE OFFICER

Level 13, 227 Elizabeth St
Sydney NSW 2000

Locked Bag A4062
Sydney South NSW 1235

Tel 61 2 9269 5500
Fax 61 2 9269 5599
www.cec.health.nsw.gov.au

ABN 79 172 068 820